Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029315 · ClinicalTrials.gov registry record · Phase 2
Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage
A Phase 2 study of Cerebral Hemorrhage, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00029315 is a Phase 2 study of Cerebral Hemorrhage that has completed, run by Johns Hopkins University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00029315, a Phase 2 study of Cerebral Hemorrhage, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.
Conditions Studied
Interventions
- DRUG Recombinant Tissue Plasminogen Activator (rt-PA)
Study Locations (1)
Maryland
- The Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029315
The ClinicalTrials.gov registry entry for NCT00029315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Tissue Plasminogen Activator (rt-PA) is the first listed.
NCT00029315 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00029315 about?
NCT00029315 is a clinical study titled "Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage". This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.
What is the current status of trial NCT00029315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-09. Estimated completion is 2004-09.
What conditions does trial NCT00029315 study?
This clinical trial studies the following conditions: Cerebral Hemorrhage.
What interventions are being tested in trial NCT00029315?
The interventions under investigation include: Recombinant Tissue Plasminogen Activator (rt-PA) (DRUG).
Who is sponsoring clinical trial NCT00029315?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00029315 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.